REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2015 >

Decisions 13th October 2015

At the meeting that took place on 13th October, the following decisions were agreed:

 

New Drug Requests

 

Approved

Tiotropium & Olodaterol inhaler (Spoilto®(TLS Bue)

  • Approved for inclusion onto the formulary for maintenance of COPD

Glycopyrronium (oral) (TLS Amber 3 months)

  • Approved for inclusion onto the formulary for the treatment of hypersalivation in motor neurone disease patients, and in patients with neurological conditions.

Ulipristal (TLS Red)

  • Approved for inclusion onto the formulary for the intermittent treatment of uterine fibroids.
  • SCP in development and when approved will be amber  

Sodium oxybate

  • The JFG clinically approved the addition of sodium oxybate, however a business case from NBT needs to be submitted to the CCG's for approval before it can be added to the formulary.

 

Shared Care Protocols/TLS Change in Status

Edoxaban

  • New SCP approved for the treatment of DVT/PE approved.